Canna-V-Cell Sciences Inc. (CSE:CNVC): Higher Cannabis Yields, Lower Costs

    Canna-V-Cell Sciences Inc.’s (CSE:CNVC) BioHarvest technology to transform cannabis production: Ubika Research

    SmallCapPower | February 12, 2019: Canna-V-Cell Sciences Inc. (CSE:CNVC) is the exclusive cannabis worldwide licensee of the proprietary and patent-protected BioHarvest technology. It is the first and only industrial large-scale plant cell growth technology capable of directly and constantly producing the active plant ingredients without the necessity to grow the plant itself.

    Investment Highlights:

    Finalizing research to adapt the BioHarvest technology to cannabis. Canna-V-Cell Sciences is focused on growing plant cells in bioreactors. The Company’s patented BioHarvest technology is a unique cell growth method capable of perpetual production of active plant ingredients without growing/harvesting the cannabis plant. The Company plans to establish industrial large-scale facilities to build adequate production capacity for producing cannabis-active ingredients. For reference, BioHarvest is the parent company of Canna-V-Cell, owning ~51% of its shares. Canna-V-Cell also has an active R&D facility in Israel.

    Hear directly from Investor Relations at Canna-V-Cell Sciences Inc (CSE:CNVC)
    Sign up for our FREE daily investment newsletter

    We will never share your data with a third-party without your consent.

    Bringing a revolution in the supply of cannabis. The Company has invested significant time (~10 years) and over $20M to develop the BioHarvest technology, which CNVC plans to fully commercialize for cannabis use by 2020. The technology, developed by the team under the leadership of the founder of BioHarvest (Dr. Yochi Hagay), has proven to work with various fruits and plants, most notably with resveratrol, a key nutrient in grapes (linked to many health benefits including lowering blood pressure and improving brain function). With BioHarvest, 400 mg of red grape cell powder is equivalent to consuming 1,000 grapes. The same team is currently adapting this technology to cannabis. Canna-V-Cell plans to introduce the same technology for cannabis, and the Company plans to produce 10,000 kg annually by 2022E. The Company plans to use a B2B approach, providing active cannabis ingredients in powdered form to customers for re-packaging in different forms. Importantly, we highlight that BioHarvest technology is backed by 10 years of R&D, 10 filed U.S. patents, and several PhDs on the research team.

    BioHarvest has the potential to increased yields 60-fold while reducing costs significantly. Biofarming is the technology of taking cells and growing them hydroponically (plants grown without soil with nutrients delivered through water). The biofarming technique uses land efficiently by significantly increasing yields per sq. ft. Canna-V-Cell’s BioHarvest Technology can produce 1.8 kg of dried flower per sq. ft, compared with conventional farming, which produces 0.03 kg of dried flower per sq. ft (Company estimates). Production costs can also be reduced significantly, with biofarming costing $100 per kg. Additionally, biofarms can be built anywhere, and the capital requirement is low compared to conventional farms ($206 per kg as compared to $10,000 per kg in conventional farming). Lastly, biofarms are resistant to adverse weather conditions and operate in an aseptic environment, avoiding any problems with toxic fungi or pesticides. The most notable quality is the consistency. All productions are guaranteed the same composition of cannabinoids, an important feature for medicinal applications.

    Overview of Canna-V-Cell BioHarvest Technology. BioHarvest is a cell growth technology for industrial production of plant cells without the bio-material. The process isolates specific compounds that are produced by the cells while maintaining structural consistency. Plant cells can be grown commercially in liquid media in bioreactors without using any solvent extraction, genetic modification or synthetic molecular processing. The biofarming process produces a high concentration of plant phytochemicals in their natural state, ensuring optimal bioavailability and efficacy. Building on the initial success of Vinia, which is a red grape powder that contains 40 mg polyphenols and 5 mg of resveratrol, the Company’s technology supports heart health and improved brain function. Canna-V-Cell is planning on applying the technology to cannabis. With the BioHarvest technology, the Company would have to isolate the cells from the cannabis plant once and then the cells are recreated with the biofarming process.

    To find out more about Canna-V-Cell Sciences Inc (CSE:CNVC), please visit the company’s Investor Hub.

    Hear directly from Investor Relations at Canna-V-Cell Sciences Inc (CSE:CNVC)
    Sign up for our FREE daily investment newsletter

    We will never share your data with a third-party without your consent.

    Ubika Research/SmallCapPower has received compensation from Canna-V-Cell Sciences Inc. to provide analyst research coverage. For full disclosure please visit here >>

    To read our full disclosure, please click on the button below: